Key facts
- Restore Vision’s last known valuation is $6.1M (Feb 2022).
- It has raised $23.5M.
- Notable investors include SMBC Venture Capital, ANRI, Japan External Trade Organization, Spiral Capital (Tokyo), JIC Venture Growth Investments — 18 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for Restore Vision
- ·The full record, as it builds
Funding rounds
No funding rounds for Restore Vision are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Restore Vision
Developer of therapeutic treatment and optical sensor protein designed for intractable eye diseases using the latest technology. The company's chimeric rhodopsin genes overcome the weakness of conventional rhodopsins and keep them working with high sensitivity for patients, enabling doctors to treat eye diseases.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2016
- Employees
- 10
- Website
- restore-vis.com/
- Ownership
- Privately Held (backing)
Restore Vision doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Restore Vision shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Restore Vision in its N-PORT filings yet. We sweep new filings monthly.